BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease

LMY-922 is an allogeneic CAR-T cell therapy consisting of allogeneic cluster of differentiation 4 (CD4) positive and cluster of differentiation 8 (CD8) positive human T cells that are genetically engineered using the non-viral transposon system to express the BAFF-ligand CAR-T that target BAFF receptor family members to eliminate pathological B cells. BAFF receptor family includes B-cell activating factor receptor (BR3), B-cell maturation antigen (BCMA) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). These receptors are present on the B cells of patients with refractory autoimmune disease. The goal of LMY-922-001 phase 1 study is to find the recommended phase 2 dose of LMY-922 for treatment of patients with refractory autoimmune disease.